US2060221056 - Common Stock
CONCERT PHARMACEUTICALS INC
NASDAQ:CNCE (3/3/2023, 7:00:00 PM)
After market: 8.4 +0.03 (+0.36%)8.37
+0.01 (+0.12%)
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2014-02-13. The firm is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The firm is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The firm is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.
CONCERT PHARMACEUTICALS INC
Suite 500, 99 Hayden Avenue
Lexington MASSACHUSETTS 02421
P: 17818600045.0
CEO: Roger D. Tung
Employees: 64
Website: https://www.concertpharma.com/
Concert Pharmaceuticals (CNCE) announced Wednesday that the FDA allowed it to keep the Breakthrough Therapy Designation for hair loss therapy deuruxolitinib. Read the full story here.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
Here you can normally see the latest stock twits on CNCE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: